Such findings suggest that APOE4/APP interactions are also a potential target for AD therapeutics (Pankiewicz et al., 2014; Wisniewski and Drummond, 2020; Sawmiller et al., 2023). This evidence concerns the gene APOE and Alzheimer disease.